Trial site
Retina Consultants of Orange County
- 12running trials
- 12closed trials
The trials here
What the 24 trials at this site are about, from their registry records.
- Conditions
- Macular degeneration15 trials
- Diabetic eye disease7 trials
- Type 2 diabetes2 trials
- Obesity1 trial
- Type 1 diabetes1 trial
- Phase
- Phase 314 trials
- Phase 24 trials
- Phase 42 trials
- Phase 1/21 trial
- Phase 2/31 trial
- Status
- Completed11 trials
- Active, not recruiting7 trials
- Recruiting3 trials
- Enrolling by invitation1 trial
- Not yet recruiting1 trial
- Terminated1 trial
- Lead sponsor
- Genentech, Inc.3 trials
- 4D Molecular Therapeutics2 trials
- Janssen Research & Development, LLC2 trials
- Kodiak Sciences Inc2 trials
- Novartis Pharmaceuticals2 trials
- and 13 more
Running trials
Recruiting
A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).
Recruiting
Active, not recruiting
Active, not recruiting
Recruiting
Recruiting
High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy
Active, not recruiting
Recruiting
Active, not recruiting
Active, not recruiting
An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration
Active, not recruiting
Enrolling by invitation
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Macular degeneration3 recruiting
- Diabetic eye disease2 recruiting
- Type 1 diabetes1 recruiting
- Type 2 diabetes1 recruiting
Closed trials
Recruiting
Completed
Completed
Completed
Completed
Completed
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
Completed
Completed
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
Completed
A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD
Completed
Completed
Terminated
HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
Site data: ClinicalTrials.govUpdated 17 Nov 2026